Entropy Neurodynamics Limited has released a press release.
Further management changes and cost-reductions
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Suspension from Quotation
- FY2023 Appendix 4E
- EX1 early stage success with in house Elastin (ELN) program
- Results of Non-Renounceable Rights Issue
- Exopharm Limited announces Non-Renounceable Pro Rata Rights
Later from Entropy Neurodynamics
- Appendix 4D and Half Year Report for period 31 December 2023
- EX1 signs binding agreement to acquire Tryp Therapeutics
- 2024 General Meeting Letter of Access, Notice and Proxy
- Disclosure Document - Prospectus
- Disclosure Document - Replacement Prospectus
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics